◆
Targeting three receptor pathways for comprehensive metabolic research: GLP-1, GIP, and Glucagon.
Dose ranges reflect commonly studied amounts in published research models. This is not medical advice. For research use only. Not for human consumption.
Protocol Comparison
Research Dose Reference
Available in 10mg, 20mg and 30mg
RETA GLP-3
Metabolic
Research dose range
0 mg3 mg6 mg9 mg12 mg
Standard research range
4 - 8 mg
Mid-range 4–8mg arms of the Phase 2 trial, where triple-receptor engagement drove major weight reduction over 48 weeks.
Research focus
Metabolic research via triple-receptor pathway
Observed window
24-48 weeks
Administration
Once weekly
Primary pathway
GLP-1 / GIP / Glucagon
Dosing ranges referenced from published clinical study designs. In referenced trials, reta is administered once weekly under medical supervision. Summary for research design only.
PROTOCOL BENEFITS
Engineered Outcomes
Triple receptor action · Metabolic remodeling · Appetite regulation
◆
Investigated for profound metabolic activation and lean tissue preservation.
◆
Backed by Phase 3 clinical data showing up to 28.3% average weight reduction at 80 weeks in TRIUMPH-1.
SCIENCE
How It Works.
In Phase 2 clinical trials published in NEJM in 2023, the 12 mg reta cohort achieved a mean weight reduction of 24.2% after 48 weeks. In December 2025, Lilly reported topline results from the Phase 3 TRIUMPH-4 trial demonstrating 28.7% average reduction after 68 weeks in participants with obesity/overweight and knee osteoarthritis, non-diabetic. These figures represent controlled research conditions.
Phase 3 data expands reta's research profile. In TRIUMPH-1, adult participants with obesity or overweight without diabetes demonstrated an average 28.3% weight loss at 80 weeks with 12 mg. In detailed results reported in September 2026 for TRIUMPH-2 (type 2 diabetes), participants achieved 20.8% reduction at 80 weeks compared to 4.0% for placebo.
WHAT TO EXPECT
In clinical research settings, metabolic shifts occur gradually and are evaluated over multiple months. Response varies by dose, research duration, and baseline subject characteristics. Findings reflect controlled study observations.
PROTOCOL NOTE
Available in 10, 20, and 30 mg vials. Strictly for laboratory research and development purposes.
FAQ
Protocol Questions
What distinguishes reta from single-receptor metabolic peptides like semaglutide?+
Reta targets three distinct receptor pathways simultaneously: GLP-1, GIP, and glucagon. This multi-receptor synergy is its primary pharmacological hallmark evaluated across Phase 2 and Phase 3 clinical research.
How frequently is reta administered in clinical trials?+
In referenced clinical study protocols, reta is administered subcutaneously once weekly under controlled medical observation. This summary is provided strictly for research study design.